Thermo Fisher ScientificTMO
TMO
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Employees: 125,000
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
14% more funds holding in top 10
Funds holding in top 10: 72 [Q4 2024] → 82 (+10) [Q1 2025]
2% more repeat investments, than reductions
Existing positions increased: 1,011 | Existing positions reduced: 988
0.48% less ownership
Funds ownership: 88.22% [Q4 2024] → 87.74% (-0.48%) [Q1 2025]
4% less first-time investments, than exits
New positions opened: 149 | Existing positions closed: 156
2% less funds holding
Funds holding: 2,571 [Q4 2024] → 2,513 (-58) [Q1 2025]
7% less capital invested
Capital invested by funds: $177B [Q4 2024] → $164B (-$12.7B) [Q1 2025]
11% less call options, than puts
Call options by funds: $961M | Put options by funds: $1.08B
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$450
3%
upside
Avg. target
$539
24%
upside
High target
$637
46%
upside
9 analyst ratings
7 positive
78%
2 neutral
22%
0 negative
0%
Scotiabank Sung Ji Nam | 36%upside $590 | Sector Outperform Upgraded | 11 Jul 2025 |
UBS Dan Leonard | 6%upside $460 | Neutral Downgraded | 9 Jul 2025 |
Evercore ISI Group Vijay Kumar | 10%upside $480 | Outperform Maintained | 8 Jul 2025 |
Barclays Luke Sergott | 3%upside $450 | Equal-Weight Maintained | 24 Jun 2025 |
Argus Research David Toung | 8%upside $470 | Buy Maintained | 29 Apr 2025 |
Financial journalist opinion
Based on 17 articles about TMO published over the past 30 days
Neutral
Business Wire
1 day ago
Thermo Fisher Scientific Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on October 15, 2025, to shareholders of record as of September 15, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world h.
Negative
Zacks Investment Research
2 days ago
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
TMO's growth via acquisitions and product launches is strong, but macro pressures and FX headwinds cloud the outlook.
Neutral
Business Wire
3 days ago
Nalgene Outdoor Launches Wild Expressions Collaboration with AtomicChild to Inspire Mindfulness Just in Time for Summer Adventures and Back-to-School
ROCHESTER, N.Y.--(BUSINESS WIRE)--Today, Nalgene Outdoor unveils its new limited-edition “Wild Expressions” series on 16 oz narrow-mouth bottles, its second partnership with Colorado artist Jimmy Bryant (AtomicChild). Following the enthusiastic response to last year's AtomicChild sticker collaboration, this unique bottle collection features three nature-inspired designs with uplifting prompts that serve as a daily reminder to savor life's moments. Nalgene Outdoor also invites followers to tag #.
Positive
Seeking Alpha
5 days ago
Thermo Fisher Scientific: Recovery In Sight, Attractively Valued
Thermo Fisher has good growth prospects ahead. Core pharma, biotech, and bioproduction businesses are driving growth, with US manufacturing investments and the Solventum acquisition strengthening future prospects. Margins remain under near-term pressure from tariffs and strategic investments, but productivity gains and pricing actions provide a cushion and set up for future expansion.
Positive
Seeking Alpha
1 week ago
4 Of The Hottest Great American SWANs For The 4th Of July
I highlight four American SWAN stocks - Realty Income, Alphabet, Globe Life, and Thermo Fisher Scientific - offering stress-free, blue-chip investment opportunities. Each company boasts strong management, robust balance sheets, consistent earnings, and attractive valuations, trading 18-24% below my fair value estimates. These stocks offer a blended 1.8% yield, low payout ratios, and A or AA credit ratings, supporting reliable dividend growth and low long-term risk.
Neutral
Business Wire
1 week ago
Thermo Fisher's NGS Assay Receives FDA Approval as a Companion Diagnostic for ZEGFROVY and for Tumor Profiling
CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has approved the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY® (sunvozertinib) and in tumor profiling. This approval brings rapid next-generation sequencing (NGS) to decentralized clinical settings closer to.
Neutral
Business Wire
1 week ago
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 23, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2025 before the market opens on Wednesday, July 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The.
Positive
Benzinga
2 weeks ago
Thermo Fisher Scientific Rises 3.1% After Key Trading Signal
TMO rose over 12 points after the alert
Neutral
Business Wire
2 weeks ago
Xcell Biosciences Announces Joint Research Collaboration with Thermo Fisher Scientific to Advance the Next Generation of Cell Therapies
SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences (Xcellbio), a San Francisco-based instrumentation company focused on cell and gene therapy applications, today announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, to advance research in regulatory T cells (Tregs) and tumor-infiltrating lymphocytes (TILs). While significant progress has been made in the cell therapy space leveraging Chimeric Antigen Receptor T (CAR T) cells, this collaborat.
Neutral
Business Wire
2 weeks ago
Thermo Fisher Scientific Awarded $94.5 Million U.S. Government Contract to Supply the Navy with Advanced Radiation Detection Systems
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that it has been awarded a five-year, $94.5 million contract by the U.S. Department of Defense (DoD) to supply the Navy with a next-generation dosimetry system alongside updated radiation health and database management software. The U.S. Navy operates the world's most technologically advanced naval fleet and is the largest defense user of dosimetry systems globally. With this award, T.
Charts implemented using Lightweight Charts™